2024-10-06 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.  

* **Cumulative Return:** JNJ has a cumulative return of 33.95%, significantly lower than the S&P 500 (VOO) with 131.01%. 
* **Relative Performance:** JNJ is lagging behind the S&P 500 by a substantial margin. The current relative performance is at the lowest point observed in the provided data (97.06% below the S&P 500). 

**2. Recent Price Movements:**

* **Closing Price:** $160.50
* **5-Day Moving Average:** $161.71
* **20-Day Moving Average:** $163.93
* **60-Day Moving Average:** $160.91

The current price is below the 5-day and 20-day moving averages, indicating a potential downward trend. However, the price is slightly above the 60-day moving average, suggesting some support in the long term.

**3. Technical Indicators:**

* **RSI:** 29.76 - This indicates the stock is in oversold territory, suggesting potential for a rebound.
* **PPO:** -0.39 - This negative value suggests downward momentum, aligning with the recent price movement.
* **Delta_Previous_Relative_Divergence:** -8.92 - This negative value indicates a recent drop in relative performance compared to the S&P 500.
* **Expected_Return:** 0.0% - This indicates that over the next 5 years, JNJ is expected to provide no outperformance compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

The most recent earnings report for Q2 2024 showed a positive surprise with an EPS of 1.95 exceeding estimates. This suggests a potential for upside, but the overall trend in revenue shows a slight decline. 

**5. News and Recent Issues:**

JNJ has been facing several challenges recently. The company is facing lawsuits regarding its talcum powder products. Additionally, the divestiture of its consumer health business, which concluded in November 2023, has impacted revenue and performance. 

Analyst opinions on JNJ are currently mixed. Some analysts believe the company's strong pharmaceutical business will drive growth, while others are concerned about the ongoing lawsuits and the impact of the divestiture.

**6. Overall Analysis:**

Overall, JNJ is currently in a challenging position. While the recent earnings report showed some positive signs, the stock's lagging performance relative to the market, technical indicators, and the ongoing lawsuits are raising concerns. The divestiture of the consumer health business has added to the uncertainty. Investors looking for a strong performer may want to consider other opportunities.

**7. Conclusion:**

JNJ's stock is currently undervalued compared to its historical performance. While the recent earnings report was a positive sign, the stock's performance has been disappointing. The company is facing several challenges, including lawsuits and the impact of the divestiture of its consumer health business. Investors looking for strong performers might want to explore other opportunities. 
